Publicaciones (16) Publicaciones de José Germán Sánchez Hernández

2024

  1. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 5, pp. 522-552

  2. Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

    JCI Insight, Vol. 9, Núm. 16

2023

  1. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research

  2. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research, Vol. 194

2022

  1. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 222-227

  2. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients

    European Journal of Pharmaceutical Sciences, Vol. 168

2021

  1. Comparison of ultra-performance liquid chromatography and ARK immunoassay for therapeutic drug monitoring of voriconazole

    Annals of Clinical Biochemistry, Vol. 58, Núm. 6, pp. 657-660

  2. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 2, pp. 447-457

  3. Relación entre las concentraciones séricas de vedolizumab en fase de inducción y respuesta temprana y mantenida en el primer año de tratamiento en pacientes con colitis ulcerosa

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 7, pp. 38-44

2020

  1. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1165-1175

  2. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease

    European Journal of Pharmaceutical Sciences, Vol. 150

  3. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease

    Journal of pediatric gastroenterology and nutrition, Vol. 71, Núm. 4, pp. 508-515

2019

  1. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases

    Annals of Clinical Biochemistry, Vol. 56, Núm. 1, pp. 28-41

2018

  1. Diseño de un modelo poblacional para la monitorización farmacocinética de infliximab en enfermedad inflamatoria intestinal

    Farmajournal, Vol. 3, Núm. 1, pp. 77-85

  2. Study of fall risk-increasing drugs in elderly patients before and after a bone fracture

    Postgraduate Medical Journal, Vol. 94, Núm. 1108, pp. 76-80

2017

  1. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia

    Expert Review of Clinical Pharmacology, Vol. 10, Núm. 8, pp. 911-917